Spots Global Cancer Trial Database for Single Arm, Prospective, Multicenter Clinical Study of TACE With Adebrelimab and Bevacizumab for Unresectable Hepatocellular Carcinoma
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Single Arm, Prospective, Multicenter Clinical Study of TACE With Adebrelimab and Bevacizumab for Unresectable Hepatocellular Carcinoma
Official Title: Single Arm, Prospective, Multicenter Clinical Study of TACE With Adebrelimab and Bevacizumab for Unresectable Hepatocellular Carcinoma
Study ID: NCT05970666
Interventions
Study Description
Brief Summary: To evaluate the efficacy and safety of TACE combined with adebrelimab and bevacizumab transformation in unresectable hepatocellular carcinoma
Detailed Description:
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
The First Affiliated Hospital of Xiamen University, Xiamen, Fujian, China
Contact Details
Name: Jianbo Chen
Affiliation: The First Affiliated Hospital of Xiamen University
Role: PRINCIPAL_INVESTIGATOR
Name: Feng Ye
Affiliation: The First Affiliated Hospital of Xiamen University
Role: PRINCIPAL_INVESTIGATOR
Name: congren Wang
Affiliation: Quanzhou First Hospital
Role: STUDY_DIRECTOR
Name: Qinghe Cai
Affiliation: Affiliated Hospital of Putian University
Role: STUDY_DIRECTOR
Name: Jiafei Chen
Affiliation: Putian First Hospital
Role: STUDY_DIRECTOR
Name: Yongzhong Wang
Affiliation: Sanming Second Hospital
Role: STUDY_DIRECTOR
Name: Feng Lin
Affiliation: Ningde Mindong Hospital
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
